Sort

Search

23/10/2023 Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain
Valero-Martínez, C, Urgelles, JF, Sallés, M, Joven-Ibáñez, BE, de Juanes, A, Ramírez, J, Juanola, X, Almodóvar, R, Laiz, A, Moreno, M, Pujol, M, Beltrán, E, Pinto-Tasende, JA, Crespí, L, Sala-Icardo, L, Castañeda, S, García-Vicuña, R. Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain. Frontiers in Immunology. 2023; 14DOI:10.3389/fimmu.2023.1283251. PMID:37936691. IF:5.700(Q1/3D).
21/10/2023 Hyperactive delirium during emergency department stay: analysis of risk factors and association with short-term outcomes
Miró Ò., Osorio G., Alquézar-Arbé A., Aguiló S., Fernández C., Burillo G., Jacob J., Llorens P., Llauger L., Peláez González Á., Figuera Castro E.R., Juarez González R., Blanco Hoffman M.J., Fernandez Salgado F., Pablos Pizarro T., Berenguer Díez M.A., Truyol Más M., López-Laguna N., Garcia Acosta J., Fernandez Domato C., Diego Robledo F.J., Ezponda P., Martinez Lorenzo A., Ortega Liarte J.V., García Rupérez I., Borne Jerez S., Corugedo Ovies C., Gallardo Sánchez B.A., Del Castillo J.G.. Hyperactive delirium during emergency department stay: analysis of risk factors and association with short-term outcomes. Internal and Emergency Medicine. 2023; 19(2)DOI:10.1007/s11739-023-03440-3. PMID:37865623. IF:3.200(Q1/2D).
21/10/2023 Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy
Socié G., Barba P., Barlev A., Sanz J., García-Cadenas I., Chevallier P., Fagioli F., Guzman-Becerra N., Kumar D., Ljungman P., Pigneux A., Sadetsky N., Yáñez San Segundo L., Shadman M., Storek J., Thirumalai D., Xing B., Mohty M.. Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy. BONE MARROW TRANSPLANTATION. 2023; 59(1)DOI:10.1038/s41409-023-02127-9. PMID:37865719. IF:4.500(Q1/2D).
20/10/2023 Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study
Meca-Lallana J.E., Prieto González J.M., Caminero Rodríguez A.B., Olascoaga Urtaza J., Alonso A.M., Durán Ferreras E., Espinosa R., Dotor J., Romera M., Ares Luque A., Pérez Ruiz D., Calles C., Hernández M.A., Hervás García M., Mendoza Rodríguez A., Berdei Montero Y., Téllez N., Herrera Varó N., Sotoca J., Presas-Rodríguez S., Querol Gutierrez L.A., Hervás Pujol M., Batlle Nadal J., Martín Ozaeta G., Gubieras Lillo L., Martínez Yélamos S., Ramió-Torrentà L., Mallada Frechin J., Belenguer Benavides A., Gascón-Giménez F., Casanova B., Landete Pascual L., Berenguer L., Navarro L., Gómez Gutierrez M., Durán C., Rodríguez Regal A., Álvarez E., García-Estévez D.A., López Real A.M., Llaneza González M.A., Marzo Sola M.E., Sánchez-Menoyo J.L., Oterino A., Villaverde González R., Castillo-Triviño T., Álvarez de Arcaya A., Llarena C.. Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study. Neurology and Therapy. 2023; 12(6)DOI:10.1007/s40120-023-00557-7. PMID:37861931. IF:4.000(Q1/2D).